1616409-88-1

Basic information

• Product Name: t-butyl 1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)-1-hydroxyethyl)-2-oxabicyclo[2.2.2]octan-4-ylcarbamate
• CAS NO: 1616409-88-1
• Molecular Weight: 663.666
• Mol File: 1616409-88-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: t-butyl 1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)-1-hydroxyethyl)-2-oxabicyclo[2.2.2]octan-4-ylcarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: t-butyl 1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)-1-hydroxyethyl)-2-oxabicyclo[2.2.2]octan-4-ylcarbamate(1616409-88-1)
• EPA Substance Registry System: t-butyl 1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)-1-hydroxyethyl)-2-oxabicyclo[2.2.2]octan-4-ylcarbamate(1616409-88-1)

Safety Data

• Hazardous Substances Data: 1616409-88-1(Hazardous Substances Data)

Upstream product

• 340023-02-1 (1-vinyl-2-oxabicyclo[2.2.2]octan-4-yl)methyl acetate 
• 724788-68-5 C₉H₆BrN₄O⁽¹⁺⁾ 
• 340022-81-3 (4-oxocyclohexane-1,1-diyl)bis(methylene) bis(4-methylbenzenesulfonate) 
• 6628-77-9 6-methoxy-pyridin-3-ylamine 
• 1257050-69-3 1,4-dioxaspiro[4.5]decane-8,8-diylbis(methylene) bis(4-methylbenzenesulfonate) 
• 1256546-72-1 [8-(hydroxymethyl)-1,4-dioxaspiro[4.5]decan-8-yl]methanol 
• 1256546-71-0 8,8-diethyl 1,4-dioxaspiro[4.5]decane-8,8-dicarboxylate 
• 20445-33-4 (R)-methoxytrifluoromethylphenylacetyl chloride 
• 55704-60-4 4-oxo-cyclohexane-1,1-dicarboxylic acid diethyl ester 
• 1415415-01-8 7-fluoro-2-methoxy-8-methyl-1,5-naphthyridine 
• 724788-70-9 8-bromo-7-fluoro-2-methoxy-1,5-naphthyridine 
• 724788-66-3 4-bromo-6-(methyloxy)-1,5-naphthyridin-3-amine 
• 1417551-48-4 t-butyl 4-bromo-6-methoxy-1,5-naphthyridine-3-yl-carbamate 
• 724788-65-2 4-bromo-6-methoxy-1,5-naphthyridine-3-carboxylic acid 

Relevant articles and documents

Oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad spectrum antibacterial agents

Bacterial resistance is eroding the clinical utility of existing antibiotics necessitating the discovery of new agents. Bacterial type II topoisomerase is a clinically validated, highly effective, and proven drug target. This target is amenable to inhibit